The FDA gave the go-ahead to Novocure for its tumor-treating electric fields device that targets advanced pancreatic cancer ...

Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.

The Food and Drug Administration approved its Optune Pax product, which delivers tumor treating fields, for certain ...

NovoCure (NVCR) is back in focus after the U.S. Food and Drug Administration approved its Optune Pax device for adult patients with locally advanced pancreatic cancer, following positive Phase 3 ...

The "NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2025 Update" company profile has been added to ResearchAndMarkets.com's offering. This report is a source for data, analysis, and actionable ...

ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that management will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. William Doyle, ...

The market expects Papa John's (PZZA) to deliver a year-over-year decline in earnings on lower revenues when it reports ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. Novocure ...

For the first quarter, NovoCure recorded net revenue that was just shy of $155 million. That was a nearly 12% improvement over the same period of 2024. Compounding that, the biotech managed to narrow ...

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph ...

Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Timothy J. Scannell, an experienced executive leader, was elected to Novocure’s board on Feb. 5. “We are extremely pleased ...